- Published on
‘Smart’ Nanoparticles Deliver mRNA Directly to Tumors in New Cancer Therapy
- Authors
- Name
- DeepHorus
Scientists at the University of Adelaide have unveiled a precision cancer therapy that uses “smart” nanoparticles to deliver mRNA directly to tumors, reprogramming corrupted immune cells back into cancer-fighting allies. Published this week in Science Advances, the study describes a targeted system that could overcome one of the biggest barriers in immunotherapy: the tumor microenvironment’s ability to suppress immune attacks. The work, led by professor Chunxia Zhao, represents a significant step toward safer, more localized mRNA cancer treatments.
The immune system normally patrols the body for cancerous cells, eliminating them before they can grow. But once a tumor forms, it can rewire the local environment, turning tumor-associated macrophages into immunosuppressive cells that block T cells. “One of the biggest challenges in cancer immunotherapy is that the immune system may be capable of attacking a tumor, but the tumor environment can stop those immune cells from doing their job,” Zhao said. Existing treatments often struggle against this oppressive environment.
The new therapy delivers mRNA encoding CXCL9, a chemical signal that recruits T cells to the tumor site. The nanoparticles also carry resiquimod, a drug that stimulates immune pathways. To ensure the payload reaches only the intended cells, the researchers studded the nanoparticles with antibodies that bind to TREM2, a protein found on immunosuppressive tumor-associated macrophages. This targeting mechanism prevents the immune-activating signal from spreading elsewhere in the body, reducing the risk of dangerous side effects.
In laboratory tests, the smart nanoparticles transformed lethargic macrophages into active immune cells. They began producing CXCL9 and other markers of an active immune state, including NOS2, whose expression increased by a factor of 89.5. Signals of immunosuppression dropped notably. When administered to mice with aggressive breast cancer, three doses slowed tumor growth. The concentration of CXCL9 was approximately four times higher than in the control group, demonstrating the therapy’s localized potency.
Technically, the approach builds on existing mRNA lipid nanoparticle technology, similar to Covid vaccines, but adds a targeting layer. Standard mRNA shots use fatty envelopes to help molecules enter cells. Here, the antibody-TREM2 interaction acts like a zip code, directing the nanoparticles to the tumor’s suppressive macrophages. The co-delivery of resiquimod further activates those cells, essentially flipping a switch that turns them from tumor promoters into T cell recruiters.
The implications could be broad. If validated in humans, this platform might treat many solid tumors by reprogramming the tumor microenvironment. It could also combine with checkpoint inhibitors or other immunotherapies, potentially turning “cold” tumors hot. However, safety and scalability remain open questions. Any therapy that modulates the immune system must avoid triggering autoimmunity or cytokine storms. The research community has reacted with cautious optimism, noting that targeted delivery is a promising way to widen therapeutic windows.
Looking ahead, the team will need to conduct larger animal studies, toxicology tests, and eventually human clinical trials. That process could take years, and many promising preclinical results fail to translate. Still, the study signals a growing trend: using precise nanotechnology to deliver genetic instructions where they are needed most. If successful, smart nanoparticles could become a modular backbone for next-generation cancer vaccines and immunotherapies, offering new hope for patients with hard-to-treat tumors.
